Beyfortus® is the first immunization designed for all infants to help prevent RSV lower respiratory tract disease through their first RSV season. Beyfortus® is also indicated for ...
In the meantime, Sanofi remains “very confident” in the Beyfortus readouts it’s published thus far, he said. Speaking to the data on protection afforded by Beyfortus through six months ...
In the RSV market for infants, AstraZeneca and Sanofi’s Beyfortus leads the way. It achieved sales of 547 million euros ($592 million) in 2023. While cross-trial comparisons carry inherent ...
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning! For those who ...
Results that may be inaccessible to you are currently showing.